Quantum-Si Incorporated Stock Price, News & Analysis

Quantum-Si (Nasdaq: QSI), a proteomics technology company focused on single-molecule protein analysis, has scheduled its second quarter 2025 financial results announcement for August 5, 2025.

The company will host a conference call at 4:30 PM ET on the same day, featuring CEO Jeff Hawkins and CFO Jeff Keyes. Investors can access the call through a live webcast on Quantum-Si's website or register for a personalized dial-in option.

Quantum-Si (Nasdaq: QSI), a proteomics technology company, has announced a $50 million registered direct offering of common stock. The company will sell 29,940,119 shares at $1.67 per share to a single institutional investor.

The offering is expected to close around July 8, 2025, subject to customary conditions. A.G.P./Alliance Global Partners is serving as the sole placement agent. The proceeds will be used for working capital and general corporate purposes. The offering is made through an effective shelf registration statement on Form S-3.

Quantum-Si (Nasdaq: QSI) has announced the placement of its Platinum® Pro instrument at the Broad Institute, expanding access to single-molecule protein sequencing capabilities in the Greater Boston life science ecosystem.

The collaboration aims to support scientific innovation across oncology, therapeutics, and biomedical research. Researchers will have access to advanced applications including high-resolution protein identification and protein barcoding for multiplexed screening and protein engineering applications.

Quantum-Si (Nasdaq: QSI) announces its participation in a GenomeWeb webinar titled 'From Raw to Reusable: Considerations for Data Integration and Real-World Standardization in Proteomics' scheduled for June 20, 2025. The one-hour virtual event will feature expert speakers from Quantum-Si, DNAnexus, Olink (Thermo Fisher Scientific), and Northwestern University's Proteomics Center of Excellence. The webinar will focus on crucial strategies for improving proteomics data management, including data accessibility, integration, and standardization across platforms. Key topics include metadata annotation best practices, cross-study dataset normalization, and participation in global standardization initiatives. The event aims to provide valuable insights for researchers, data scientists, and bioinformaticians in the proteomics field.

Quantum-Si (Nasdaq: QSI) announces that Liberate Bio's Director of Platform, Melissa Deck, will present at the Festival of Genomics & Biodata Boston on June 24, 2025. The presentation titled 'Precision Proteomics: Advancing Drug Development with Next-Gen Protein Sequencing' will showcase how QSI's Platinum Pro instrument is being used for protein analysis through single-molecule detection. The talk will highlight protein barcoding applications for nucleic acid-LNP therapeutic development, including single-molecule protein sequencing on a benchtop platform, proteomics and genomics integration, and multiplexed protein screening. Deck brings extensive experience in CRISPR/Cas9 editing, gene therapy, and LNP screening from her leadership roles in biotech and pharma.

Quantum-Si (Nasdaq: QSI), a proteomics technology company specializing in single-molecule protein analysis, has granted 45,529 restricted stock units (RSUs) to new employees as inducement awards. The grants were made under the company's 2023 Inducement Equity Incentive Plan and approved by the Compensation Committee of QSI's Board of Directors. The RSUs will vest 25% on June 20, 2026, with the remaining amount vesting in 12 equal quarterly installments thereafter, contingent on continued employment. These equity awards were granted as material inducement for new hires joining Quantum-Si, in compliance with Nasdaq Listing Rule 5635(c)(4).

Quantum-Si and ESPCI Paris researchers have developed a groundbreaking method for measuring single-molecule binding kinetics at scale using QSI's Platinum Next-Gen Protein Sequencing instrument. The technique combines protein barcode sequencing with real-time single-molecule interaction data, enabling parallel analysis of protein variants without genotype-phenotype coupling. The method was validated across 20 nanobody variants showing strong correlation with SPR, demonstrating a 1,000-fold range in affinity. The platform allows for high-throughput measurement of tens of thousands of single molecules per run and has potential to scale to over 1,000-member barcode sets. This innovation makes single-molecule analysis more accessible and practical for applications in drug discovery, protein engineering, and disease biology research.

Quantum-Si (Nasdaq: QSI) reported its Q1 2025 financial results, highlighting revenue of $842,000, an 84% increase from Q1 2024. The company successfully launched and delivered its first Platinum® Pro units and expanded its international channel network to 23 partners. Key developments include the on-track progress of Proteus™ Platform, v4 Sequencing Kit (expected Q3 2025), and a new v3 Library Preparation Kit (expected end of 2025). Financial metrics show a gross profit of $486,000 with 58% margin, and operating expenses of $25.6M. The company reported a net loss of $19.2M. Following a $50M registered direct offering in January 2025, QSI holds $232.6M in cash and investments, providing runway into second half of 2027. The company noted challenges in the U.S. market due to NIH funding and tariff uncertainty but remains optimistic about opportunities in pharma, biotech, and international markets.

Quantum-Si (NASDAQ: QSI) has announced the granting of 16,555 restricted stock units (RSUs) to new employees as part of its 2023 Inducement Equity Incentive Plan. The RSUs were granted as inducement awards under Nasdaq Listing Rule 5635(c)(4), specifically designed for new hires who were not previously employed by the company. The vesting schedule includes 25% vesting on June 20, 2026, followed by the remaining amount vesting in 12 equal quarterly installments. The grants are contingent upon continued employment with Quantum-Si through the vesting dates.